Clinical Efficacy and Safety of Fanhdi, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study

Autor: Víctor Jiménez-Yuste MD, PhD, María Teresa Alvarez-Román MD, Ángeles Palomo Bravo MD, Bernardo J. Galmes MD, Maria del Mar Nieto Hernández MD, Olga Benítez Hidalgo MD, Cristina Marzo Alonso MD, Noelia Florencia Pérez González MD, Julia Coll MD, Ramiro Núñez MD, Marina Carrasco MD, Faustino García Candel MD, Jose Ramon Gonzalez-Porras MD, Carmen Hernández García MD, Maria José Varó Castro MD, Roser Mir PhD

Publikováno v: Clinical and Applied Thrombosis/Hemostasis, Vol 28 (2022)

Objective To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods A retrospective, multicentric, ob

Externí odkaz: https://doaj.org/article/5d0e1875ee074ffdbdd01dcdf3329a79

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Consensus recommendations for the improvement of inter- and intra-centre care coordination in the management of hemophilia

Autor: José Bruno Montoro-Ronsano, José Luis Poveda-Andrés, José Antonio Romero-Garrido, Sara García-Barcenilla, Iria González-Álvarez, Ramiro Núñez-Vázquez, Montserrat Rambla-Pérez, Inmaculada Soto-Ortega

Publikováno v: Farmacia Hospitalaria.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7147bfbc2ec1757acff6bb5e22f90321
https://doi.org/10.1016/j.farma.2023.04.002

New Inhibitors in the Ageing Population: A Retrospective, Observational, Cohort Study of New Inhibitors in Older People with Hemophilia

Autor: Pål Andre Holme, Philippe de Moerloose, Manuela Carvalho, Roseline d'Oiron, Paul R. van der Valk, Pierre Fontana, Olga Katsarou, Ingrid Pabinger, Robert Campbell Tait, Maria Elisa Elisa Mancuso, Natascha Marquardt, Cihan Ay, Cedric Hermans, Robert Klamroth, Jan Astermark, Gerard Dolan, Gili Kenet, Ramiro Núñez

Publikováno v: Thrombosis and haemostasis, Vol. 122, no. 6, p. 905-912 (2022)

Introduction A second peak of inhibitors has been reported in patients with severe hemophilia A (HA) aged >50 years in the United Kingdom. The reason for this suggested breakdown of tolerance in the aging population is unclear, as is the potential im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab953b68898e49be44cffeb985ddaada
https://doi.org/10.1055/a-1642-4067

Costs of the management of hemophilia A with inhibitors in Spain

Autor: Ana Durán, Ramiro Núñez, Inés Pérez-Román, Elena Ruiz-Beato, Yoana Ivanova, Santiago Bonanad, José Luis Poveda, Almudena González-Domínguez, M. T. Alvarez, Beatriz Gil

Publikováno v: Global & Regional Health Technology Assessment, Vol 8 (2021)
GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

Introduction: Emicizumab is a first-in-class monoclonal antibody, recently authorized for the treatment of hemophilia A with inhibitors. This study aims to estimate the direct and indirect costs of the management of hemophilia A with inhibitors, in a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f54f4152b775a06ae080539530f54bd
https://doi.org/10.33393/grhta.2021.2234